## Interview Summary

Application No. 09/902,266

Michele Flood

Applicant(s)


Examiner

De LACHARRIERE et al.

1651



All participants (applicant, applicant's representative, PTO p	ersonnel):		
(1) Michele Flood	(3)		
(2) Antoinette M. Lee (See Below)			
Date of Interview Oct 31, 2002			
Type: a) ☒ Telephonic b) ☐ Video Conference c) ☐ Personal [copy is given to 1) ☐ applicant 2	2) applicant's representative]		
Exhibit shown or demonstration conducted: d)  Yes	e) 🛮 No. If yes, brief description:		
Claim(s) discussed: <i>None</i>			
Identification of prior art discussed:			
any other comments:	g) was not reached. h) N/A.  nature of what was agreed to if an agreement was reached, or  livision of Bausch & Lomb, archived the OCUVITE (registered)		
	confirmed that the product comprised Vitamin A in the form		
of beta-carotene at the time that the reference was published	ed. The technical data of the product was facsimiled to the		
Office and is attached hereto.			
	· · · · · · · · · · · · · · · · · · ·		
(A fuller description, if necessary, and a copy of the amendrallowable, if available, must be attached. Also, where no coavailable, a summary thereof must be attached.)	ments which the examiner agreed would render the claims apply of the amendments that would render the claims allowable is		
i) It is not necessary for applicant to provide a separa	ate record of the substance of the interview (if box is checked).		
Unless the paragraph above has been checked, THE FORMA INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPE already been filed, APPLICANT IS GIVEN ONE MONTH FROM SUBSTANCE OF THE INTERVIEW. See Summary of Record	P section 713.04). If a reply to the last Office action has W THIS INTERVIEW DATE TO FILE A STATEMENT OF THE		
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.			



(Product Code 4550)

Label Claim	Quantity/ Tablet (mg)	Percent Excess	Percent (w/w)
Cibin			•
5000 TU	20.250	35	3.022
	74,000	11	11.043
	66.000	10	9.849
30 10			
40 mg	54,767	10.	8.173
-	•	10	0.411
. •	- · ·	50	0.022
40 Dicg	0.344		
			40.291
•			20.030
	:		2.984
			0.522
*	3.000		0.447
	1.500		0.224
•	0,953		0.14
•	0.572		0.08
			2.75
	Sooo IU 60 mg 30 IU 40 mg 2 mg 40 mcg	Claim Tablet (mg)  5000 IU 20.250 60 mg 74.000 30 IU 66.000  40 mg 54.767 2 mg 2.754 40 mcg 0.144  270.000 134.229 20.000 3.500 3.000 1.500	Claim Tablet (mg) Excess  5000 IU 20.250 35 60 mg 74.000 11 30 IU 66.000 10  40 mg 54.767 10 2 mg 2.754 10 40 mcg 0.144 50  270.000 134.229 20.000 3.500 3.000 1.500  0.953 0.572 18.460

Each tablet contains less than 1 calorie

(a) Contains 65 % Microcrystalline Cellulose and 35 % Calcium Carbonata

updated March, 2000

<sup>(</sup>b) Opadry Orange YS-1-9703 contains the following: hydroxypropyl methylcellulose, titanium dioxide (E171), sodium lauryl sulfate, and FD&C Yellow No. 6.

<sup>(</sup>c) Used in the manufacturing process but does not appear in final product.

Phone: 800-227-1427 ext. 2545 Fax: 813-975-7770

## Bausch & Lomb



□ Urge	ent	☐ For Review	☐ Please Comment	☐ Please Reply	X Please Recycle
Re:	Ocuvite				
Phone	703	-308-9432	Pages:	2	
Fax:	703	-746-5245	Date:	October 31, 2002	
To:	Micl	helle Flood	From:	Antionette M. Lee	

## •Comments:

This fax is in response to your phone call on October 31, 2002. We at Bausch & Lomb Pharmaceuticals, Inc. value hearing from our customers because product quality and customer satisfaction are important to us.

Thank you for your interest in our products. I hope this information is helpful to you.